Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection

Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept c...

Full description

Bibliographic Details

Published in:	EBioMedicine Vol. 66; p. 103310
Main Authors:	Talaat, Kawsar R., Alaimo, Cristina, Martin, Patricia, Bourgeois, A. Louis, Dreyer, Anita M., Kaminski, Robert W., Porter, Chad K., Chakraborty, Subhra, Clarkson, Kristen A., Brubaker, Jessica, Elwood, Daniel, Frölich, Rahel, DeNearing, Barbara, Weerts, Hailey, Feijoo, Brittany L., Halpern, Jane, Sack, David, Riddle, Mark S., Fonck, Veronica Gambillara
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.04.2021 Elsevier
Subjects:	Advanced Basic Science Bioconjugate vaccine Controlled human challenge study Internal Medicine Research Paper Shigella Shigella flexneri 2a Vaccine Controlled human challenge study Vaccine Shigella flexneri 2a Bioconjugate vaccine Shigella
ISSN:	2352-3964, 2352-3964
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!